1 Introduction 9

• 1.1 Industry Definition and Research Scope 9
  • 1.1.1 Industry Definition 9
  • 1.1.2 Research Scope 10
• 1.2 Research Methodology 13
  • 1.2.1 Overview of Market Research Methodology 13
  • 1.2.2 Market Assumption 14
  • 1.2.3 Secondary Data 14
  • 1.2.4 Primary Data 14
  • 1.2.5 Data Filtration and Model Design 15
  • 1.2.6 Market Size/Share Estimation 16
  • 1.2.7 Research Limitations 17
• 1.3 Executive Summary 18

2 Market Overview and Dynamics 21

• 2.1 Market Size and Forecast 21
  • 2.1.1 Impact of COVID-19 on World Economy 22
  • 2.1.2 Impact of COVID-19 on the Market 24
• 2.2 Major Growth Drivers 26
• 2.3 Market Restraints and Challenges 32
• 2.4 Emerging Opportunities and Market Trends 35
• 2.5 Porter’s Fiver Forces Analysis 39

3 Segmentation of Global Market by Offering 43

• 3.1 Market Overview by Offering 43
• 3.2 Services 45
• 3.3 Test Kits & Consumables 46

4 Segmentation of Global Market by Application 47

• 4.1 Market Overview by Application 47
• 4.2 Non-Hodgkin’s Lymphoma (NHL) 49
  • 4.2.1 DLBCL 51
  • 4.2.2 Marginal Zone Lymphoma 52
  • 4.2.3 Follicular Lymphoma 53
  • 4.2.4 Peripheral T-cell Lymphoma 54
  • 4.2.5 Mantle Cell Lymphoma 55
  • 4.2.6 Other NHLs 56
• 4.3 Multiple Myeloma (MM) 57
• 4.4 Acute Lymphoblastic Leukemia (ALL) 58
• 4.5 Chronic Lymphoblastic Leukemia (CLL) 59
• 4.6 Acute Myeloid Leukemia (AML) 60
• 4.7 Chronic Myeloid Leukemia (CML) 61
• 4.8 Hodgkin’s Lymphoma (HL) 62
• 4.9 Solid Tumor 63
• 4.10 Other Applications 64

5 Segmentation of Global Market by Technology 65

• 5.1 Market Overview by Technology 65
• 5.2 Flow Cytometry 67
• 5.3 Polymerase Chain Reaction (PCR) 68
• 5.4 Next-Generation Sequencing (NGS) 69
• 5.5 Other Technologies 70

6 Segmentation of Global Market by End User 71

• 6.1 Market Overview by End User 71
• 6.2 Hospitals and Clinics 73
• 6.3 Research Institutions 74
• 6.4 Diagnostic Laboratories 75
• 6.5 Other End Users 76

7 Segmentation of Global Market by Region 77

• 7.1 Geographic Market Overview 2021-2031 77
• 7.2 North America Market 2021-2031 by Country 81
  • 7.2.1 Overview of North America Market 81
  • 7.2.2 U.S. 85
  • 7.2.3 Canada 88
  • 7.2.4 Mexico 90
• 7.3 European Market 2021-2031 by Country 92
  • 7.3.1 Overview of European Market 92
  • 7.3.2 Germany 96
  • 7.3.3 U.K. 98
  • 7.3.4 France 100
  • 7.3.5 Spain 102
  • 7.3.6 Italy 104
  • 7.3.7 Netherlands 106
  • 7.3.8 Rest of European Market 108
• 7.4 Asia-Pacific Market 2021-2031 by Country 110
  • 7.4.1 Overview of Asia-Pacific Market 110
  • 7.4.2 Japan 114
  • 7.4.3 China 117
  • 7.4.4 Australia 119
  • 7.4.5 India 121
  • 7.4.6 South Korea 123
  • 7.4.7 Rest of APAC Region 125
• 7.5 South America Market 2021-2031 by Country 127
  • 7.5.1 Argentina 130
  • 7.5.2 Brazil 132
  • 7.5.3 Chile 134
  • 7.5.4 Rest of South America Market 136
• 7.6 MEA Market 2021-2031 by Country 137
  • 7.6.1 UAE 140
  • 7.6.2 Saudi Arabia 142
  • 7.6.3 South Africa 144
  • 7.6.4 Other National Markets 146

8 Competitive Landscape 147

• 8.1 Overview of Key Vendors 147
• 8.2 New Product Launch, Partnership, Investment, and M&A 151
• 8.3 Company Profiles 152

Adaptive Biotechnologies Corporation 152

ArcherDX, Inc. (Invitae Corporation) 154

Arup Laboratories 155

Asuragen Inc. 156

Bio-Rad Laboratories, Inc. 157

Cergentis B.V. 158

Guardant Health 159

ICON plc 160

Inivata Ltd. 161

Invivoscribe, Inc. 162

Laboratory Corporation of America Holdings 163

Mission Bio, Inc. 164

Natera, Inc. 165

NeoGenomics Laboratories, Inc. 166

Opko Health, Inc. 167

Quest Diagnostics Incorporated 168

Sysmex Corporation 169

RELATED REPORTS 170

Global minimal residual disease (MRD) testing market will reach $ 2,858.1 million by 2031, growing by 12.4% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 86 tables and 87 figures, this 170-page report “Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Region.

Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Services
• Test Kits & Consumables

Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Non-Hodgkin's Lymphoma (NHL)
o DLBCL
o Marginal Zone Lymphoma
o Follicular Lymphoma
o Peripheral T-cell Lymphoma
o Mantle Cell Lymphoma
o Other NHLs
• Multiple Myeloma (MM)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphoblastic Leukemia (CLL)
• Acute Myeloid Leukemia (AML)
• Chronic Myeloid Leukemia (CML)
• Hodgkin's Lymphoma (HL)
• Solid Tumor
• Other Applications

By Technology, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies

By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals and Clinics
• Research Institutions
• Diagnostic Laboratories
• Other End Users

Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of national markets by Application, Technology, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)